DOCSLIB.ORG

Association of Preterm Birth with Depression and Particulate Matter: Machine Learning Analysis Using National Health Insurance Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association of Preterm Birth with Depression and Particulate Matter: Machine Learning Analysis Using National Health Insurance Data National Health Insurance Data HealthInsurance National Using Analysis Learning Matter:Machine Particulate and Depression of Pretermwith Association Birth Supplementary Materials PTB1 Average 1000.00 1200.00 1400.00 1000.00 1200.00 1400.00 1600.00 200.00 400.00 600.00 800.00 200.00 400.00 600.00 800.00 0.00 0.00 Socioeconomic Status Socioeconomic Status Age Age Proton Pump Inhibitor Proton Pump Inhibitor Benzodiazepine Benzodiazepine Tricyclic Antidepressant GERD_2014 GERD_2014 GERD_2013 GERD_2013 Tricyclic Antidepressant GERD_2012 GERD_2012 GERD_2011 GERD_2011 Sleeping Pills Sleeping Pills GERD_2010 GERD_2010 GERD_2009 GERD_2009 Progesterone PM_2014_07 GERD_2008 PM_2014_01 PM_2014_07 PM_2014_06 PM_2014_06 PM_2014_12 PM_2014_05 PM_2014_08 PM_2014_04 PM_2014_10 PM_2014_01 PM_2014_11 PM_2014_12 PM_2014_09 PM_2014_10 PM_2014_05 PM_2014_09 PM_2014_02 PM_2014_11 PM_2014_04 PM_2014_02 PM_2014_03 PM_2014_08 Progesterone PM_2014_03 GERD_2008 Region Region GERD_2007 GERD_2007 Myoma Uteri Myoma Uteri GERD_2006 GERD_2006 Diabetes_2014 GERD_2005 GERD_2005 Diabetes_2014 GERD_2004 GERD_2004 Depression_2013 GERD_2003 GERD_2003 Depression_2013 Depression_2014 Depression_2014 Diabetes_2013 Diabetes_2013 Depression_2011 Depression_2012 Depression_2012 Depression_2011 GERD_2002 Calcium Channel Blocker Calcium Channel Blocker Diabetes_2012 Depression_2010 GERD_2002 Diabetes_2012 Depression_2010 Depression_2009 Depression_2009 Depression_2007 Diabetes_2010 Diabetes_2009 Diabetes_2011 Diabetes_2010 Depression_2007 Diabetes_2008 Depression_2008 Depression_2006 Diabetes_2009 Diabetes_2006 Diabetes_2006 Depression_2008 Diabetes_2005 Diabetes_2005 Depression_2006 Diabetes_2011 Diabetes_2008 Depression_2005 Hypertension_2014 Nitrate Diabetes_2007 Hypertension_2014 Depression_2005 Diabetes_2007 Nitrate Hypertension_2013 Diabetes_2004 Diabetes_2003 Hypertension_2013 Hypertension_2009 Diabetes_2003 Hypertension_2010 Hypertension_2009 Hypertension_2006 Hypertension_2008 Hypertension_2012 Hypertension_2012 Hypertension_2008 Hypertension_2006 Diabetes_2004 Hypertension_2010 Depression_2004 Depression_2004 Hypertension_2007 Periodontitis_2006 Diabetes_2002 Hypertension_2011 Periodontitis_2006 Hypertension_2007 Hypertension_2005 Diabetes_2002 Periodontitis_2005 Depression_2003 Hypertension_2011 Hypertension_2005 Depression_2003 Depression_2002 Hypertension_2004 Periodontitis_2005 Depression_2002 Hypertension_2004 Periodontitis_2009 Hypertension_2003 Prior Cone Periodontitis_2014 Periodontitis_2008 Periodontitis_2009 Periodontitis_2013 Periodontitis_2013 Hypertension_2003 In Vitro Fertilization Periodontitis_2003 Periodontitis_2010 Periodontitis_2004 Periodontitis_2008 Periodontitis_2007 Hypertension_2002 Periodontitis_2014 Periodontitis_2002 Periodontitis_2002 Periodontitis_2011 Periodontitis_2010 Periodontitis_2003 Periodontitis_2012 Periodontitis_2007 Periodontitis_2011 Prior Cone In Vitro Fertilization Periodontitis_2004 Hypertension_2002 Periodontitis_2012 PTB4 PTB3 PTB2 1000.00 1200.00 1400.00 1600.00 1800.00 100.00 200.00 300.00 400.00 500.00 600.00 700.00 1000.00 1200.00 1400.00 1600.00 1800.00 200.00 400.00 600.00 800.00 200.00 400.00 600.00 800.00 0.00 0.00 0.00 Socioeconomic Status Socioeconomic Status Socioeconomic Status Age Age Age Proton Pump Inhibitor Proton Pump Inhibitor Proton Pump Inhibitor Benzodiazepine Benzodiazepine Benzodiazepine PM_2014_08 GERD_2013 GERD_2013 PM_2014_12 GERD_2014 GERD_2014 PM_2014_02 Tricyclic Antidepressant Tricyclic Antidepressant PM_2014_11 GERD_2012 GERD_2012 Tricyclic Antidepressant GERD_2011 GERD_2011 PM_2014_09 Sleeping Pills Sleeping Pills PM_2014_06 GERD_2010 GERD_2010 PM_2014_10 GERD_2009 GERD_2009 PM_2014_01 PM_2014_07 PM_2014_07 PM_2014_07 PM_2014_08 PM_2014_08 PM_2014_05 PM_2014_01 PM_2014_01 GERD_2014 PM_2014_03 PM_2014_03 PM_2014_03 PM_2014_10 PM_2014_10 PM_2014_04 PM_2014_09 PM_2014_09 GERD_2013 Figure S1. S1. Figure PM_2014_04 PM_2014_04 GERD_2012 PM_2014_05 PM_2014_05 GERD_2011 PM_2014_11 PM_2014_11 GERD_2010 PM_2014_12 PM_2014_12 Sleeping Pills PM_2014_06 PM_2014_06 GERD_2009 PM_2014_02 PM_2014_02 Region Progesterone Progesterone GERD_2008 GERD_2008 GERD_2008 Progesterone Region Region GERD_2007 GERD_2007 GERD_2007 Myoma Uteri Myoma Uteri Myoma Uteri Random Random GERD_2006 GERD_2006 GERD_2006 GERD_2005 GERD_2005 GERD_2005 Diabetes_2014 Diabetes_2014 Diabetes_2014 GERD_2004 GERD_2004 GERD_2004 GERD_2003 GERD_2003 GERD_2003 Depression_2014 Depression_2013 Depression_2013 Diabetes_2013 Depression_2014 Depression_2014 Depression_2013 Diabetes_2013 Diabetes_2013 Depression_2012 forest variable importance forest variable Depression_2012 Depression_2012 Diabetes_2012 Depression_2011 Depression_2011 Diabetes_2011 Diabetes_2012 Diabetes_2012 Calcium Channel Blocker Calcium Channel Blocker Calcium Channel Blocker Depression_2011 GERD_2002 GERD_2002 GERD_2002 Depression_2010 Depression_2010 Depression_2008 Depression_2008 Depression_2008 Depression_2007 Diabetes_2011 Diabetes_2011 Depression_2009 Depression_2009 Depression_2010 Diabetes_2010 Diabetes_2010 Diabetes_2010 Depression_2007 Depression_2007 Depression_2009 Diabetes_2009 Diabetes_2009 Diabetes_2006 Diabetes_2005 Diabetes_2005 Diabetes_2005 Depression_2006 Depression_2006 Hypertension_2014 Diabetes_2006 Diabetes_2006 Diabetes_2009 Diabetes_2008 Diabetes_2008 Diabetes_2008 Hypertension_2014 Hypertension_2014 Diabetes_2004 Diabetes_2007 Diabetes_2007 Diabetes_2007 Nitrate Nitrate Depression_2006 Depression_2005 Depression_2005 Hypertension_2013 Diabetes_2004 Diabetes_2004 Diabetes_2003 Diabetes_2003 Diabetes_2003 Depression_2005 Hypertension_2013 Hypertension_2013 Hypertension_2008 Hypertension_2008 Hypertension_2008 Hypertension_2012 Hypertension_2012 Hypertension_2012 Hypertension_2009 Hypertension_2006 Hypertension_2011 . Hypertension_2006 Hypertension_2010 Hypertension_2010 Nitrate Hypertension_2009 Hypertension_2009 Depression_2002 Depression_2004 Depression_2004 Periodontitis_2006 Periodontitis_2006 Periodontitis_2006 Depression_2004 Diabetes_2002 Diabetes_2002 Hypertension_2006 Hypertension_2007 Hypertension_2007 Depression_2003 Hypertension_2011 Hypertension_2011 Hypertension_2010 Depression_2003 Depression_2003 Hypertension_2007 Hypertension_2005 Hypertension_2005 Diabetes_2002 Depression_2002 Depression_2002 Hypertension_2005 Periodontitis_2005 Periodontitis_2005 In Vitro Fertilization Hypertension_2004 Hypertension_2004 Periodontitis_2002 Hypertension_2003 Hypertension_2003 Periodontitis_2014 Periodontitis_2014 Periodontitis_2014 Hypertension_2003 In Vitro Fertilization In Vitro Fertilization Periodontitis_2011 Hypertension_2002 Hypertension_2002 Hypertension_2002 Periodontitis_2002 Periodontitis_2002 Periodontitis_2013 Periodontitis_2010 Periodontitis_2010 Periodontitis_2003 Periodontitis_2009 Periodontitis_2009 Hypertension_2004 Periodontitis_2013 Periodontitis_2013 Periodontitis_2010 Periodontitis_2011 Periodontitis_2011 Periodontitis_2007 Periodontitis_2008 Periodontitis_2008 Periodontitis_2008 Periodontitis_2004 Periodontitis_2004 Periodontitis_2004 Prior Cone Prior Cone Periodontitis_2005 Periodontitis_2007 Periodontitis_2007 Periodontitis_2012 Periodontitis_2003 Periodontitis_2003 Periodontitis_2009 Periodontitis_2012 Periodontitis_2012 Prior Cone PTB2 PTB1 Average 1000.00 1200.00 1400.00 1000.00 1200.00 1400.00 100.00 200.00 300.00 400.00 500.00 600.00 700.00 200.00 400.00 600.00 800.00 200.00 400.00 600.00 800.00 0.00 0.00 0.00 Socioeconomic Status Age Socioeconomic Status Socioeconomic Status PM_2014_09 Age Age PM_2014_03 Proton Pump Inhibitor Proton Pump Inhibitor PM_2014_05 Benzodiazepine Benzodiazepine PM_2014_06 GERD_2014 PM_2014_06 PM_2014_11 Progesterone PM_2014_11 PM_2014_02 GERD_2012 PM_2014_09 PM_2014_12 GERD_2013 PM_2014_07 PM_2014_04 Tricyclic Antidepressant PM_2014_03 PM_2014_08 PM_2014_07 PM_2014_02 PM_2014_07 PM_2014_11 PM_2014_01 PM_2014_01 PM_2014_02 PM_2014_05 PM_2014_10 PM_2014_06 PM_2014_10 Proton Pump Inhibitor PM_2014_01 PM_2014_04 Progesterone PM_2014_08 PM_2014_08 Benzodiazepine PM_2014_10 Tricyclic Antidepressant Tricyclic Antidepressant PM_2014_09 PM_2014_12 GERD_2014 PM_2014_03 GERD_2014 GERD_2013 PM_2014_05 GERD_2013 GERD_2012 PM_2014_12 Progesterone GERD_2011 GERD_2011 GERD_2012 Sleeping Pills PM_2014_04 GERD_2011 GERD_2010 Sleeping Pills Sleeping Pills Myoma Uteri GERD_2010 GERD_2010 GERD_2009 GERD_2009 GERD_2009 Region Myoma Uteri Region GERD_2008 GERD_2008 GERD_2008 GERD_2007 Region Myoma Uteri GERD_2006 GERD_2007 GERD_2007 Diabetes_2014 GERD_2006 GERD_2006 GERD_2005 Diabetes_2014 Diabetes_2014 GERD_2004 GERD_2005 GERD_2005 GERD_2003 GERD_2004 GERD_2004 Depression_2014 Depression_2013 Depression_2013 Diabetes_2013 Depression_2014 GERD_2003 Depression_2013 GERD_2003 Depression_2014 Depression_2012 Diabetes_2013 Depression_2012 Calcium Channel Blocker Depression_2012 Diabetes_2013 Depression_2011 Depression_2011 Depression_2011 GERD_2002 Calcium Channel Blocker Diabetes_2012 Diabetes_2012 Diabetes_2012 GERD_2002 Depression_2010 GERD_2002 Hypertension_2014 Calcium Channel Blocker Depression_2010 Depression_2010 Depression_2009 Depression_2009 Diabetes_2011 Depression_2007 Diabetes_2010 Depression_2009 Diabetes_2010 Diabetes_2011 Diabetes_2009 Diabetes_2005 Depression_2008 Diabetes_2008 Depression_2008 Depression_2007 Hypertension_2013 Diabetes_2006 Diabetes_2009 Depression_2008 Diabetes_2009 Diabetes_2005 Diabetes_2010 Depression_2006 Diabetes_2006 Depression_2005 Diabetes_2011 Hypertension_2014 Nitrate Diabetes_2008 Depression_2006 Diabetes_2005 Hypertension_2014 Diabetes_2008 Hypertension_2012 Diabetes_2007
Load more

Recommended publications
  • Effect of Amlodipine and Indomethacin in Electrical and Picrotoxin Induced Convulsions in Mice
    DOI: 10.5958/2319-5886.2014.00402.0 International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 3 Issue 3 Coden: IJMRHS Copyright @2014 ISSN: 2319-5886 Received: 9th Apr 2014 Revised: 3rd Jun 2014 Accepted: 14th Jun 2014 Research Article EFFECT OF AMLODIPINE AND INDOMETHACIN IN ELECTRICAL AND PICROTOXIN INDUCED CONVULSIONS IN MICE *Jagathi Devi N1, Prasanna V2 1Assistant Professor, 2Professor and Head, Department of Pharmacology, Osmania Medical College, Hyderabad *Corresponding author email: [email protected] ABSTRACT Background and Objectives: Antiepileptic drugs (AEDs) are the drugs used in the treatment of epilepsy. Many AEDs have been developed, but the ideal AED which can not only prevent but also abolish seizures by correcting the underlying pathophysiology is still not in sight. Calcium channel blockers (CCBs) may form such a group, as the initiation of epileptogenic activity in the neuron is connected with a phenomenon known as “intrinsic burst firing” which is activated by inward calcium current. In this study, Amlodipine, a CCB of the dihydropyridine class was evaluated for its anticonvulsant activity in mice. It was compared with Phenytoin sodium, one of the oldest anti epileptic drugs. Amlodipine was also combined with Indomethacin, a conventional NSAID, to look for any potentiating effect of this prostaglandin-synthesis inhibitor. Materials and Methods: A total of 48 adult Swiss albino mice of either sex weighing 20-30 G were used for this study; 48 were divided into 8 groups, each group containing 6 mice. Group 1-4 MES (50 m Amp for 0.1 secs) induced convulsion method, Group 5-8 evaluated by using the chemo-convulsant, picrotoxin (0.7 mg / kg).
    [Show full text]
  • Neurochemical Mechanisms Underlying Alcohol Withdrawal
    Neurochemical Mechanisms Underlying Alcohol Withdrawal John Littleton, MD, Ph.D. More than 50 years ago, C.K. Himmelsbach first suggested that physiological mechanisms responsible for maintaining a stable state of equilibrium (i.e., homeostasis) in the patient’s body and brain are responsible for drug tolerance and the drug withdrawal syndrome. In the latter case, he suggested that the absence of the drug leaves these same homeostatic mechanisms exposed, leading to the withdrawal syndrome. This theory provides the framework for a majority of neurochemical investigations of the adaptations that occur in alcohol dependence and how these adaptations may precipitate withdrawal. This article examines the Himmelsbach theory and its application to alcohol withdrawal; reviews the animal models being used to study withdrawal; and looks at the postulated neuroadaptations in three systems—the gamma-aminobutyric acid (GABA) neurotransmitter system, the glutamate neurotransmitter system, and the calcium channel system that regulates various processes inside neurons. The role of these neuroadaptations in withdrawal and the clinical implications of this research also are considered. KEY WORDS: AOD withdrawal syndrome; neurochemistry; biochemical mechanism; AOD tolerance; brain; homeostasis; biological AOD dependence; biological AOD use; disorder theory; biological adaptation; animal model; GABA receptors; glutamate receptors; calcium channel; proteins; detoxification; brain damage; disease severity; AODD (alcohol and other drug dependence) relapse; literature review uring the past 25 years research- science models used to study with- of the reasons why advances in basic ers have made rapid progress drawal neurochemistry as well as a research have not yet been translated Din understanding the chemi- reluctance on the part of clinicians to into therapeutic gains and suggests cal activities that occur in the nervous consider new treatments.
    [Show full text]
  • Anaesthetic Implications of Calcium Channel Blockers
    436 Anaesthetic implications of calcium channel Leonard C. Jenkins aA MD CM FRCPC blockers Peter J. Scoates a sc MD FRCPC CONTENTS The object of this review is to emphasize the anaesthetic implications of calcium channel block- Physiology - calcium/calcium channel blockers Uses of calcium channel blockers ers for the practising anaesthetist. These drugs have Traditional played an expanding role in therapeutics since their Angina pectoris introduction and thus anaesthetists can expect to see Arrhythmias increasing numbers of patients presenting for anaes- Hypertension thesia who are being treated with calcium channel Newer and investigational Cardiac blockers. Other reviews have emphasized the basic - Hypertrophic cardiomyopathy pharmacology of calcium channel blockers. 1-7 - Cold cardioplegia - Pulmonary hypertension Physiology - calcium/calcium channel blockers Actions on platelets Calcium plays an important role in many physio- Asthma Obstetrics logical processes, such as blood coagulation, en- - Premature labor zyme systems, muscle contraction, bone metabo- - Pre-eclampsia lism, synaptic transmission, and cell membrane Achalasia and oesophageal spasm excitability. Especially important is the role of Increased intraocular pressure therapy calcium in myocardial contractility and conduction Protective effect on kidney after radiocontrast Cerebral vasospasm as well as in vascular smooth muscle reactivity. 7 Induced hypotensive anaesthesia Thus, it can be anticipated that any drug interfering Drag interactions with calcium channel blockers with the action of calcium could have widespread With anaesthetic agents effects. Inhalation agents In order to understand the importance of calcium - Effect on haemodynamics - Effect on MAC in cellular excitation, it is necessary to review some Neuromuscular blockers membrane physiology. Cell membranes are pri- Effects on epinephrine-induced arrhythmias marily phospholipids arranged in a bilayer.
    [Show full text]
  • Dental Management for the Hypertensive Patient
    HYPERTENSION AND ORAL HEALTH: EPIDEMIOLOGIC AND CLINICAL PERSPECTIVES Janet H Southerland, DDS, MPH, PhD Professor, Department of Oral and Maxillofacial Surgery School of Dentistry, Meharry Medical College December 9, 2016 Provide an overview of concerns with treating patients with hypertension and GOAL provide recommendations that will be helpful in managing a broad spectrum of these patients. EVALUATION Evaluation for hypertension has three objectives: 1. to assess lifestyle and identify other cardiovascular risk factors or concomitant disorders that may affect prognosis and guide treatment. 2. to reveal identifiable causes of high BP. 3. to assess the presence or absence of target organ damage and cardiovascular disease (CVD). TARGET ORGAN DAMAGE Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart Failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral artery disease Retinopathy The relationship between BP and risk of CVD events is continuous, consistent, and independent of other risk factors. The higher the BP, the greater is the chance of heart attack, heart failure, stroke, and kidney disease. INTRODUCTION The risk of developing CVD doubles for every increment of 20 mm Hg Systolic (SBP) or 10 mm Hg of Diastolic (DBP). The risk of dying of ischemic heart disease and stroke increases progressively and linearly when blood pressure exceeds 115/75 mm Hg. The 7th and 8th Joint National Committee (JNC-7 and 8) reports provide guidelines for blood pressure management and treatment. The JNC-8 panel confirms that the >140/90 mmHg definition for hypertension from the INTRODUCTION JNC 7 report remains the standard for diagnosis for individuals who do not have additional comorbidities.
    [Show full text]
  • Calcium Channel Blockers
    Calcium Channel Blockers Summary In general, calcium channel blockers (CCBs) are used most often for the management of hypertension and angina. There are 2 classes of CCBs: the dihydropyridines (DHPs), which have greater selectivity for vascular smooth muscle cells than for cardiac myocytes, and the non-DHPs, which have greater selectivity for cardiac myocytes and are used for cardiac arrhythmias. The DHPs cause peripheral edema, headaches, and postural hypotension most commonly, all of which are due to the peripheral vasodilatory effects of the drugs in this class of CCBs. The non-DHPs are negative inotropes and chronotropes; they can cause bradycardia and depress AV node conduction, increasing the risk of heart failure exacerbation, bradycardia, and AV block. Clevidipine is a DHP calcium channel blocker administered via continuous IV infusion and used for rapid blood pressure reductions. All CCBs are substrates of CYP3A4, but both diltiazem and verapamil are also inhibitors of 3A4 and have an increased risk of drug interactions. Verapamil also inhibits CYP2C9, CYP2C19, and CYP1A2. Pharmacology CCBs selectively inhibit the voltage-gated L-type calcium channels on cardiac myocytes, vascular smooth muscle cells, and cells within the sinoatrial (SA) and atrioventricular (AV) nodes, preventing influx of extracellular calcium. CCBs act by either deforming the channels, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the major cellular calcium store, the endoplasmic reticulum. Calcium influx via these channels serves for excitation-contraction coupling and electrical discharge in the heart and vasculature. A decrease in intracellular calcium will result in inhibition of the contractile process of the myocardial smooth muscle cells, resulting in dilation of the coronary and peripheral arterial vasculature.
    [Show full text]
  • Oral Calcium Channel Blocker Comparison
    Oral Calcium Channel Blocker Comparison Various calcium channel blockers (CCBs) have been periodically shorted. Below is a table of dosing comparisons. General notes: No dose equivalencies among the CCBs have been established; estimate an approximate dose using the dosing ranges. The contraindications and adverse effects of non-dihydropyridine (DHP) CCBs (diltiazem and verapamil) are quite different from DHP CCBs (amlodipine, felodipine, nifedipine). Consider staying with the same type of CCB if possible unless other considerations warrant changing types. Be sure to check for drug interactions if switching agents. Calcium Channel Blocker Comparisons1,2 Doses CCB Contraindications Hypertension Stable angina DHP Adverse Effects: pedal edema, flushing, palpitations, headache Nifedipine MR 30-60 mg up to 90 mg daily 2.5-5 mg to 10 mg Amlodipine 5-10 mg daily daily severe aortic stenosis 2.5-10 mg to May be useful but Felodipine 20 mg daily not indicated Non-DHP Adverse Effects: angina, heart failure; constipation, especially with verapamil 120-240 mg post myocardial infarction with 120-180 mg to 360 Diltiazem MR to 360 mg ejection fraction (EF) <40% mg daily daily 2nd or 3rd degree AV block, or sick sinus syndrome (unless functioning ventricular pacemaker) atrial flutter/atrial fibrillation and accessory bypass tract (e.g. Wolff- 80-240 mg Parkinson-White syndrome, Lown- 180 mg to 480 mg once daily to Ganong-Levine syndrome) Verapamil MR daily in one or two 180-240 mg combination with ivabradine doses BID Verapamil extreme bradycardia severe heart failure and or EF<40% combination with drugs that affect cardiac conduction CCB= calcium channel blocker; DHP= dihydropyridine; MR=modified release such as XL, CD, SR, etc.
    [Show full text]
  • Diltiazem Added to Local Anesthetic in Sonar Guided Coracoid Infraclavicular Brachial Plexus Block
    Journal of Clinical Anesthesia and Pain Medicine Research Article Diltiazem Added to Local Anesthetic in Sonar Guided Coracoid Infraclavicular Brachial Plexus Block. Dose Sparing Effect This article was published in the following Scient Open Access Journal: Journal of Clinical Anesthesia and Pain Medicine Received November 01, 2017; Accepted March 15, 2018; Published April 07, 2018 Abstract 1 1 Ashraf E Alzeftawy *, Hesham E Elsheikh Background: This study was performed to evaluate the addition of diltiazem to local 1Assistant Professors of Anesthesia and Surgical anesthetic during sonar guided infraclavicular brachial plexus block as regards to its intra Intensive care, Department of Anesthesia and and postoperative analgesic quality. Surgical Intensive care, Tanta University, Tanta, Egypt Methods: In a randomized, prospective double blind study, 90 patients aged between 18-70 years with ASA Grade I and II, were randomly classified into 3 groups. Group I received 30 ml containing 14 ml 0.5% bupivacaine and 14 ml lidocaine 2% plus 2 ml saline and group II received same volume of local anesthetic and diltiazem 20mg in 2 ml saline. while group III received 30 ml containing 10 ml 0.5% bupivacaine , 10 ml lidocaine 2% and diltiazem 20mg in 10 ml saline. Onset of sensory and motor block , quality of the block , postoperative analgesia, and any complications of the procedure were recorded. Results: Onset of sensory and motor block was significantly shorter in group II compared to other groups. Quality of the block in the three groups was comparable. Significantly prolonged duration of sensory and motor block and prolonged duration of analgesia were present in group II compared to other groups.
    [Show full text]
  • Use of Rainbow Trout Cell Lines to Delineate the Roles of P53 in Fish
    Use of rainbow trout cell lines to delineate the roles of p53 in fish and to evaluate the toxicity of emerging environmental contaminants, benzotriazoles and benzothiazoles by Fanxing Zeng A thesis presented to the University of Waterloo in fulfillment of the thesis requirement for the degree of Doctor of Philosophy in Biology Waterloo, Ontario, Canada, 2015 ©Fanxing Zeng 2015 AUTHOR'S DECLARATION I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. II ABSTRACT Epithelial cell lines, RTgill-W1 and RTL-W1 from respectively the gill and liver of rainbow trout, Onchorhynchus mykiss (Walbum), were used to investigate the role of p53 in the cellular survival pathways of fish and to evaluate the potential impact on fish of the emerging contaminants, benzotriazoles (BTRs) and benzothiazoles (BTHs). For studying p53, RTgill-W1 was used with two p53 inhibitors, which are termed pifithrins-µ (PFT-µ) or 2- phenylethynesulfonamide (PES) and pifithrin-α (PFT-α). Both agents were developed for cancer chemotherapy but also have been used widely to explore p53 functions in mammals but not in fish. PFT-µ or 2-phenylethynesulfonamide (PES) was identified as an inhibitor of p53 translocation to the mitochondria but subsequently shown to be a HSP70 inhibitor as well. PFT-α was recognized as an inhibitor of p53-mediated transcription. Cellular toxicity was evaluated for seven BTRs: 1H-Benzotriazole (BTR), 4-methyl-1H-benzotriazole (4MBTR), 5-methyl-1H- benzotriazole (5MBTR), tolytriazole (TT), 5,6-Dimethyl-1H-benzotriazole monohydrate (DM), 5-Chlorobenzotriazole (5CBTR) and Hydroxybenzotriazole (OHBTR).
    [Show full text]
  • Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats
    1017 Hypertens Res Vol.28 (2005) No.12 p.1017-1023 Original Article Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats Takatomi SHOKOJI*, Yoshihide FUJISAWA**, Hideyasu KIYOMOTO***, Matlubur RAHMAN*,***, Guang-Ping SUN***, Yu-Yan FAN*, Shoji KIMURA*, Masakazu KOHNO***, Youichi ABE*, and Akira NISHIYAMA* Antihypertensive treatment with dihydropyridine calcium channel blockers elicits sympathetic nerve activa- tion, which may contribute to cardiovascular events. However, recent clinical studies showed that treatment with azelnidipine, a new dihydropyridine calcium channel blocker, significantly reduced blood pressure in hypertensive patients while either maintaining or actually decreasing heart rate (HR). In this study, we exam- ined the effects of azelnidipine and amlodipine on systemic hemodynamics and renal sympathetic nerve activity (RSNA) in anesthetized spontaneously hypertensive rats (SHR). We also examined the effects of these agents on baroreflex functions by infusing phenylephrine (30 µg/kg/min, i.v.) and sodium nitroprus- side (10 µg/kg/min, i.v.) into azelnidipine- or amlodipine-treated SHR. Fifty min after administration of azelni- dipine (10 µg/kg/min for 10 min, i.v.), mean arterial pressure (MAP) significantly decreased from 153±5 to 122±5 mmHg; however, HR and integrated RSNA did not change significantly (from 352±9 to 353±10 beats/ min and 115±5% of baseline, respectively). Infusion of amlodipine (50 µg/kg/min for 10 min) elicited similar effects on MAP (from 152±5 to 120±4 mmHg). However, amlodipine significantly increased HR (from 351±9 to 375±11 beats/min) and integrated RSNA (165±5% of baseline).
    [Show full text]
  • Diltiazem Ointment
    Patient Drug Education for Diltiazem Ointment Diltiazem ointment (Cardizem) is a calcium channel class of medication we use to help heal anal fissures, promote wound healing, or treat external thrombosed hemorrhoids. The ointment relaxes the smooth muscle around the rectum and promotes blood flow to help the growth of new skin over the tear in the lining of the rectum. The ointment reduces anal canal pressure, which diminishes pain and spasm. We use a 2% concentration mixed with Lidocaine and Aloe Vera. It is only available at compounding pharmacies. For fissures the ointment should be applied three times a day usually for six weeks and then one to two times a day for usually an additional six weeks. A pea size drop should be placed on the tip of your index finger and then the ointment is gently placed inside of the rectum. The finger should be inserted at least half its length and then swiped towards the fissure, located posteriorly or anteriorly, as it is removed. For an external thrombosis rub the ointment over the swollen area and then inside the rectum. The finger may be covered with a plastic glove or finger cot. You may use Vaseline to help coat the finger or dilute the ointment. If you are advised to place the ointment on a steroid suppository limit the steroids to one to two weeks in order to decrease the risk of infection. It is important to continue the treatment for the entire time period. It takes up to two years to regain the normal skin strength associated with a fissure.
    [Show full text]
  • Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
    Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents* Cardiac Drug(s) Enzyme/ Chemotherapy Effect of Drug- Suggested Oncologist Suggested Cardiologist Action Drug† Drug Management Management Interaction Beta-Blockers All beta- Additive Ceritinib Additive Avoid using the combination of ceritinib with beta- blockers clinical bradycardia blockers. If concomitant use is necessary and symptomatic effect bradycardia occurs, hold ceritinib, adjust or discontinue the beta-blocker, and upon recovery resume ceritinib at a reduced dose with frequent monitoring of heart rate.‡ Crizotinib Monitor blood pressure and heart rate regularly. Dose reduction or discontinuation of one of the agents may be necessary if clinically significant bradycardia occurs.‡ Carvedilol P-gp Afatinib ↑ Monitor for adverse Consider alternative agent if inhibition chemotherapy effects of afatinib. If possible. (moderate) drug not well-tolerated, concentration decrease afatinib daily dose by 10 mg. Doxorubicin Monitor for adverse Consider alternative agent if Nilotinib effects of possible. If carvedilol is used for Paclitaxel chemotherapy drug if prevention of anthracycline Pazopanib concomitant therapy is cardiotoxicity, individual risk vs. Vincristine necessary. benefit must be considered. If Vinblastine concomitant therapy is necessary and drug-drug interaction involves QT- prolonging chemotherapy drug, ensure appropriate electrocardiographic (ECG) and electrolyte monitoring. Carvedilol; CYP2D6 Imatinib ↑ beta-blocker Monitor blood pressure
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]